DIABRISK-SL trial: further consideration of age and impact of imputations - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue BMC Medicine Année : 2019

DIABRISK-SL trial: further consideration of age and impact of imputations

Résumé

Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide. Early interventions may help to delay or prevent onset of cardiometabolic endpoints of clinical importance to T2DM patients.Wijesuriya et al. (BMC Med 15:146, 2017) published results of a randomised controlled trial in Sri Lanka testing the effect of two lifestyle modification programmes of varying intensity in participants aged 5-40 years with risk factors for T2DM. The intervention measured the impact of the two programmes on the primary composite endpoint consisting of various predictors of cardiometabolic disease. The authors concluded that the more intensive programme significantly reduced the incidence of predictors of cardiometabolic disease. Further, they delivered a large-scale intervention with restricted resources with widespread acceptance as demonstrated by the high uptake rate. However, we believe that further analysis is required to fully understand the potential for benefit, particularly in relation to age, retention and missing data.
Fichier principal
Vignette du fichier
s12916-019-1361-2.pdf (495.62 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

inserm-02291075 , version 1 (18-09-2019)

Identifiants

Citer

Efstathia Gkioni, Ketevan Glonti, Susanna Dodd, Carrol Gamble. DIABRISK-SL trial: further consideration of age and impact of imputations. BMC Medicine, 2019, 17 (1), pp.121. ⟨10.1186/s12916-019-1361-2⟩. ⟨inserm-02291075⟩
58 Consultations
40 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More